{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:10:28Z","timestamp":1791472228352,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["CICAMS-MOMP 2022010"],"award-info":[{"award-number":["CICAMS-MOMP 2022010"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["CPHCF-2022-093"],"award-info":[{"award-number":["CPHCF-2022-093"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Research Project on Emerging Supportive Therapy for Oncology"},{"name":"The National Science and Technology Major Project for Key New Drug Development"},{"name":"The Major Project of Medical  Oncology Key  Foundation of Cancer Hospital Chinese Academy of Medical Sciences"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.esmoop.2025.105505","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T18:49:49Z","timestamp":1753469389000},"page":"105505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial"],"prefix":"10.1016","volume":"10","author":[{"given":"L.","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105505_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105505_bib2","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.21873\/anticanres.15392","article-title":"Prognostic factors of potential early recurrence of hypopharyngeal carcinoma","volume":"41","author":"Baba","year":"2021","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s43163-022-00215-z","article-title":"Prognostic factors impacting survival rates of hypopharyngeal cancer with nomogram prediction: a SEER-based study","volume":"38","author":"Tawfik","year":"2022","journal-title":"Egypt J Otolaryngol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105505_bib4","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10167","key":"10.1016\/j.esmoop.2025.105505_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.esmoop.2025.105505_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105505_bib7","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/s41591-024-03110-7","article-title":"Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial","volume":"30","author":"Shi","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105505_bib8","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1200\/JCO.2020.38.15_suppl.6583","article-title":"Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer","volume":"38","author":"Zinner","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105505_bib9","article-title":"Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105505_bib10","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12885-021-08373-8","article-title":"Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdy507","article-title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","volume":"30","author":"Oliva","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105505_bib13","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","article-title":"Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis","volume":"22","author":"Rodrigo","year":"2024","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105505_bib15","doi-asserted-by":"crossref","first-page":"11234","DOI":"10.1002\/cam4.5815","article-title":"A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma","volume":"12","author":"Nindra","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105505_bib16","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105505_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105505_bib19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105505_bib20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","article-title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II","volume":"29","author":"Dietz","year":"2018","journal-title":"Ann Oncol"},{"issue":"53","key":"10.1016\/j.esmoop.2025.105505_bib21","doi-asserted-by":"crossref","first-page":"91150","DOI":"10.18632\/oncotarget.20017","article-title":"Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Fangzheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2025.105505_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2019.06.015","article-title":"Induction chemotherapy in head and neck cancers: results and controversies","volume":"95","author":"Gau","year":"2019","journal-title":"Oral Oncol"},{"issue":"39","key":"10.1016\/j.esmoop.2025.105505_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022283","article-title":"Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105505_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105505_bib25","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105505_bib26","article-title":"Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib27","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105505_bib28","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1200\/JCO.2023.41.16_suppl.6077","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"41","author":"Chen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105505_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-23-2398","article-title":"Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: a single-arm phase II clinical trial","volume":"30","author":"Ou","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105505_bib30","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1200\/JCO.2023.41.16_suppl.6070","article-title":"Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): a single-arm, phase II clinical trial","volume":"41","author":"Bai","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105505_bib31","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105505_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.esmoop.2025.105505_bib33","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105505_bib34","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105505_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cam4.382","article-title":"Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck","volume":"4","author":"Schell","year":"2015","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105505_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12032-017-0884-7","article-title":"Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent\/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel","volume":"34","author":"Ley","year":"2017","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105505_bib37","first-page":"3445","article-title":"Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator","volume":"11","author":"Chen","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105505_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/OTT.S122974","article-title":"nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors","volume":"10","author":"Soliman","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105505_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105505_bib40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:13:57Z","timestamp":1759612437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925013742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2059702925013742"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105505","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105505"}}